ProjectConnex 3 – A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy…
Basic data
Acronym:
Connex 3
Title:
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia
Duration:
29/02/2024 to 31/07/2025
Abstract / short description:
Es handelt sich um eine Phase III Studie mit dem neu entwickelten Medikament Iclepertin, das die kognitive Leistung bei Patienten mit Schizophrenie verbessern soll. Die Studie ist randomisiert, doppelt verblindet und placebo-kontrolliert. Die Teilnahmedauer beträgt acht Monate, wobei das Medikament oder Placebo über einen Zeitraum von 26 Wochen eingenommen werden. Alle drei Wochen findet eine Studienvisite am Prüfzentrum statt.
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Mayr-Erlinger, Regina
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Other staff
Department of Psychology
Faculty of Science
Faculty of Science
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of General psychiatry and psychotherapy with outpatient clinic
Department of Psychiatry and Psychotherapy
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Ingelheim am Rhein, Rheinland-Pfalz, Germany